Neuroendocrine and Rare Tumor Advances: A New and Promising TRAIL Emerges
Open Access
- 23 February 2022
- journal article
- editorial
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 28 (9) , 1748-1750
Abstract
Summary: ONC201 is an oral selective antagonist of the dopamine D2 receptor and direct activator of caseinolytic protease P. In a phase II study, ONC021 was shown to be well tolerated with notable efficacy in patients with the rare neuroendocrine neoplasms pheochromocytomas-paragangliomas, although biomarkers for activity remain to be elucidated. See related article by Anderson et al., p. 1773Keywords
Funding Information
- LUNGevity Foundation Career Development Award
This publication has 5 references indexed in Scilit:
- Phase II Study of ONC201 in Neuroendocrine Tumors including Pheochromocytoma-Paraganglioma and Desmoplastic Small Round Cell TumorClinical Cancer Research, 2022
- ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic CancerMolecular Cancer Therapeutics, 2021
- Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell LethalityCancer Cell, 2019
- First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid TumorsClinical Cancer Research, 2017
- Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor EffectsScience Translational Medicine, 2013